Dr Edwin Lim explains oral weight-loss medications in Singapore, including Rybelsus, oral Wegovy and Foundayo: evidence, availability, costs and safety.
Interested in Oral Weight Loss Medications? Enquire Now! to WhatsApp us and speak with our team directly.
Oral weight-loss medicines work in different ways. Some help reduce hunger and make smaller meals feel satisfying, while others reduce the amount of fat absorbed from food. Choosing between them involves more than deciding whether you prefer a tablet to an injection: we also consider your health, the evidence for each treatment and whether its daily routine suits you.
This guide compares oral GLP-1 tablets and other oral medications, including their expected results, side effects and costs. It also explains the distinction between a diabetes tablet that may affect weight and a treatment developed specifically for weight management, and why overseas approval does not establish availability in Singapore.
You do not need to arrive knowing which medicine to request. We can start with the difficulties you have faced with weight management and what you hope treatment will help you achieve, then discuss the options that may be appropriate for you.
Oral weight-loss medications are tablets or capsules used to support weight management alongside changes to food intake and physical activity. They are different from the slimming supplements sold online, even when those products use similar language about appetite, metabolism or GLP-1.
The main groups discussed here are oral GLP-1 receptor agonists, the fat-absorption inhibitor orlistat, and medicines that act on appetite pathways such as phentermine and naltrexone/bupropion. These treatments do not all have the same approved purpose or supply requirements. Oral GLP-1 medicines require a prescription, while some other products may be supplied through a pharmacist after assessment.
A medicine can also affect body weight without being registered specifically for weight loss. If a treatment is considered outside its registered indication, your doctor should explain that distinction, the reasons for considering it, and the available alternatives.
Novo Nordisk’s oral semaglutide diabetes formulation is registered in Singapore, with 3 mg, 7 mg and 14 mg strengths listed in the National Drug Formulary. Our clinic supplies this formulation following medical assessment. Its registered purpose is treating type 2 diabetes; using it solely for weight loss is off-label and requires a discussion of the evidence, risks and alternatives.
You may also have read about the newer 25 mg oral semaglutide weight-management tablet and Eli Lilly’s orforglipron tablet. Both have US approval for adult weight management. We explain them below so that you can understand how they differ from the oral semaglutide formulation available at our clinic. Their availability in Singapore remains to be confirmed.
Other oral options include orlistat, phentermine and naltrexone/bupropion. We explain their roles and precautions below, and can discuss which options may suit your health during your assessment.
GLP-1 is a hormone involved in appetite and blood sugar regulation. Medicines that activate its receptor can influence the brain’s signals for hunger and fullness, helping some people feel satisfied with less food. When this makes it easier to reduce overall calorie intake, body weight may gradually fall.
In everyday life, you might notice that hunger between meals feels less persistent, that you are comfortable leaving part of a larger portion, or that you reach for snacks less often. These changes are not identical for everyone. Some people notice a clear difference in appetite, while others experience a more subtle change as treatment progresses.
These medicines also affect digestion, including slowing stomach emptying, but their effect on weight involves more than keeping food in the stomach. They can support blood sugar control by helping the pancreas release insulin when glucose is raised and reducing glucagon, a hormone that prompts the liver to release glucose.
The aim is to make a nourishing eating pattern more manageable. You should still be able to eat and drink adequately. Persistent nausea, difficulty finishing even small meals or dehydration should prompt a review rather than being treated as signs that the medicine is working especially well.
|
Comparison |
Novo Nordisk’s Oral Semaglutide for Diabetes |
Novo Nordisk’s 25 mg Oral Semaglutide |
Eli Lilly’s Orforglipron |
|---|---|---|---|
|
Main indication |
Type 2 diabetes in Singapore; weight-loss-only use is off-label |
Adult weight management under US prescribing conditions |
Adult weight management under US prescribing conditions |
|
Daily routine |
Once daily on an empty stomach; wait at least 30 minutes before food, drinks or other tablets |
Once daily in the morning on an empty stomach; wait at least 30 minutes before food, drinks or other tablets |
Once daily, with or without food under the US instructions |
|
Evidence discussed here |
3 mg, 7 mg and 14 mg formulation; weight findings mainly from adults with type 2 diabetes |
25 mg studied in adults with overweight or obesity without diabetes |
Pivotal obesity study in adults without diabetes; research and marketed strengths differ |
|
Singapore and clinic position |
Singapore-registered diabetes formulation supplied by our clinic after assessment |
Overseas-approved; Singapore registration and clinic supply not confirmed here |
Overseas-approved; Singapore registration and clinic supply not confirmed here |
This formulation comes in 3 mg, 7 mg and 14 mg tablets and is registered in Singapore for adults with type 2 diabetes who need better blood sugar control. It may also reduce appetite and body weight, although the main evidence for these doses comes from people with diabetes.
Treatment starts at a low dose and is increased gradually according to blood sugar control, tolerability and the prescribing guidance. The first month helps introduce the medicine, so an early response does not necessarily show how well the eventual treatment plan will work. The individual guide below explains the dose schedule in more detail.
The tablet’s absorption depends on how it is taken. Swallow it whole on an empty stomach with no more than 120 mL of plain water, then wait at least 30 minutes before food, drinks or other oral medicines. For example, taking it before your morning shower may help you build the waiting period into a consistent routine.
Read more about Novo Nordisk’s daily oral semaglutide tablet, including dosing and safety, at https://edwinlimclinic.sg/rybelsus-oral-weight-loss-medication-in-singapore/
This is the oral semaglutide formulation developed for weight management in eligible adults. The 25 mg dose was studied in the OASIS 4 obesity trial. It is distinct from the 3 mg, 7 mg and 14 mg diabetes formulation described above.
Under the US prescribing schedule, treatment starts below 25 mg and increases in stages, usually allowing at least a month at each step. This gives time to assess how well the medicine is tolerated. The individual guide below explains the formulation and dose schedule.
The tablet is taken whole in the morning on an empty stomach with a small amount of plain water, followed by at least a 30-minute wait before food, drinks or other tablets. Do not combine lower-dose diabetes tablets to try to reproduce this formulation.
Explore the oral semaglutide weight-management guide at https://edwinlimclinic.sg/oral-wegovy-pill-weight-loss-singapore/
Orforglipron activates the GLP-1 receptor but has a different molecular structure from semaglutide. It is a small-molecule medicine rather than a peptide. One practical difference is that the US-approved tablet can be taken with or without food, without the fasting routine required for oral semaglutide.
Treatment starts at a low dose and increases gradually, giving you time to see how your appetite and digestion respond. The dose schedule depends on the exact tablet supplied and how well you tolerate it. The individual guide below explains the available strengths and dosing in more detail.
The flexibility around food may appeal to someone whose mornings are unpredictable. We would still consider your medical history, other medicines and the evidence for the treatment before discussing whether it could be an appropriate option.
Learn more about Eli Lilly’s oral GLP-1 treatment at https://edwinlimclinic.sg/orforglipron-singapore/
GLP-1 tablets are one group of oral treatments. Other medicines work through different pathways and have their own benefits and precautions. Understanding these differences helps us discuss options that fit your health and the difficulties you are experiencing.
Orlistat reduces the absorption of some of the fat in a meal. It works in the digestive tract rather than through the GLP-1 appetite pathway. Oily stools, urgency and other bowel effects can occur, particularly with higher-fat meals, so the composition of your diet matters during treatment.
It also requires attention to other medicines and fat-soluble vitamins. The Singapore-registered 120 mg product is classified as pharmacy-only. Eligibility and response still need assessment; its registered guidance includes reviewing whether sufficient weight loss has occurred after 12 weeks.
Phentermine is an appetite suppressant used as a short-term part of a medically supervised weight-management plan. It is not a GLP-1 medicine. Its effects on sleep and the cardiovascular system mean that blood pressure, heart history and other medicines are important considerations.
The Singapore product information specifies medical review after a defined course that should not exceed three months. This makes its treatment role different from medicines intended for longer-term weight management.
This combination acts on brain pathways involved in appetite and is used for chronic weight management alongside dietary and lifestyle measures. Its suitability requires particular attention to blood pressure, seizure history, mental health and medication interactions.
Tell your doctor if you use opioid pain medicines, as the naltrexone component can block their effects and may cause withdrawal in someone who is dependent on opioids. Treatment choice should account for your wider medical needs as well as your weight goals.
There is no single expected result for “weight-loss pills”. The medicine, formulation, dose, duration and population studied all matter. Your starting weight, health conditions, tolerance and consistency with treatment also influence the outcome.
The examples below summarise selected oral GLP-1 trials. They show what happened in those studies and should not be read as a forecast of your own result.
|
Study and Treatment |
Participants and Duration |
Average Weight Change |
|---|---|---|
|
PIONEER 1: oral semaglutide 14 mg daily |
Adults with type 2 diabetes; 26 weeks |
About 3.7 kg loss versus 1.4 kg with placebo |
|
OASIS 4: oral semaglutide 25 mg daily |
Adults with overweight or obesity without diabetes; results at 64 weeks |
13.6% loss versus 2.2% with placebo in the published trial analysis |
|
ATTAIN-1: orforglipron investigational formulation, 6 mg, 12 mg or 36 mg daily |
Adults with obesity without diabetes; 72 weeks |
7.5%, 8.4% and 11.2% loss respectively, versus 2.1% with placebo |
These figures describe average results in the study groups, including people who stopped treatment. Participants also received dietary or lifestyle support. For orforglipron, the tablet strengths used in research differ from those supplied commercially, so the study doses should not be used as instructions for taking the medicine.
Your own response may differ. Because these studies involved different groups of people and treatment periods, they cannot tell us directly which medicine would work best for you. Results with the 25 mg semaglutide formulation also should not be assumed for the 7 mg or 14 mg diabetes tablet.
For people with type 2 diabetes, oral semaglutide can improve blood sugar control. The SOUL trial also found fewer major cardiovascular events with oral semaglutide than placebo in adults aged 50 or older with type 2 diabetes and established cardiovascular disease, chronic kidney disease, or both.
This is useful evidence when discussing treatment with people who have a similar medical history. It does not establish the same cardiovascular benefit for every oral GLP-1 medicine or for someone taking a tablet solely to lose weight. We consider the benefits demonstrated for your circumstances.
A tablet may feel more familiar, especially if you are uncomfortable with needles. However, a daily tablet is not automatically easier to fit into every routine. Someone who struggles to delay breakfast or already takes several morning medicines may find oral semaglutide less convenient than expected.
|
Consideration |
Daily Oral GLP-1 Treatment |
Weekly GLP-1-Based Injection |
|---|---|---|
|
Remembering treatment |
A daily habit; oral semaglutide also needs a fasting window |
A weekly habit with training on how to use the prescribed pen |
|
Meals and routine |
Semaglutide needs careful timing around food and other tablets; orforglipron has different instructions |
No oral absorption waiting period before breakfast |
|
Expected results |
Discuss the evidence for the exact tablet, dose and indication |
Discuss the evidence for the exact injection, dose and indication |
|
Side effects |
Digestive symptoms can occur despite avoiding an injection |
Digestive symptoms can also occur; injecting does not remove this risk |
During your consultation, we consider how much weight reduction would be clinically useful, any diabetes or other health conditions, and your experience with previous treatment. Your daily routine matters too: a plan needs to be medically appropriate and realistic for you to continue.
Compare the weekly treatment options in our injection guide at https://edwinlimclinic.sg/weight-loss-injections-singapore-guide/
Switching may be possible, but there is no universal milligram-for-milligram conversion. The reason for changing treatment, the previous dose, side effects and the formulation being considered all affect the plan.
The ATTAIN-MAINTAIN trial studied orforglipron after injectable semaglutide or tirzepatide. Participants assigned to the tablet retained more of their previous weight reduction than those assigned to placebo over 52 weeks. The study did not include a group continuing the injection, so it does not establish that switching is as effective as staying on injectable treatment.
This evidence does not automatically apply to the lower-dose oral semaglutide diabetes tablet. Do not overlap medicines or make a switch yourself; the timing and starting regimen should be agreed with your doctor.
We consider whether medication could help you manage your weight or improve a related health condition, such as type 2 diabetes. Your assessment includes BMI, blood pressure, weight history, medical conditions and current medication. We also ask what you have already tried, what has been difficult, and how hunger, meals and treatment routines fit into your day.
Eligibility differs between products. Many medicines registered for weight management use an initial BMI of at least 30, or at least 27 with a weight-related condition, but these thresholds are not a universal rule for every oral medicine. A tablet registered for diabetes has its own prescribing conditions. An Asian BMI risk category alone does not establish eligibility for a particular drug.
Tell us about pregnancy plans or breastfeeding, previous pancreatitis or gallstones, severe digestive problems, kidney or liver disease, diabetic eye disease, eating disorders and any personal or family history of medullary thyroid cancer or MEN2. Not every item rules out every treatment, but each can change the assessment and the options discussed.
If medication is unlikely to help you achieve an appropriate health goal, or its risks outweigh the likely benefits, we will explain why and discuss other ways to support you.
Oral GLP-1 medicines can cause nausea, vomiting, diarrhoea, constipation, reflux or abdominal discomfort. Symptoms may be more noticeable when treatment begins or the dose increases. Smaller meals, eating slowly and avoiding meals that worsen symptoms may help, but persistent problems should be reviewed.
If you are struggling to keep fluids down, passing much less urine or feeling faint, seek prompt medical assessment. Repeated vomiting and diarrhoea can cause dehydration and affect kidney function. A dose increase should not go ahead simply because the next date on a schedule has arrived when you are still unwell.
Severe, persistent abdominal pain, particularly if it spreads to the back or is accompanied by vomiting, needs urgent assessment for pancreatitis or another cause. Upper abdominal pain with fever or jaundice may indicate a gallbladder problem. Breathing difficulty or swelling of the face, lips or tongue requires emergency care.
New or rapidly worsening vision problems also need prompt assessment. Do not wait for a routine appointment or a WhatsApp reply when symptoms are severe.
The European Medicines Agency has recognised non-arteritic anterior ischaemic optic neuropathy, or NAION, as a very rare side effect of semaglutide medicines. This condition involves impaired blood flow to the optic nerve and can cause sudden, often painless loss of vision. Sudden partial or complete loss of sight warrants urgent eye assessment.
This does not mean that the same risk has been established for every other oral weight-loss medicine. If you have diabetes-related eye disease, we also consider whether changes in blood sugar control require closer eye follow-up.
Weight-loss medication is not used during pregnancy. Semaglutide should be stopped at least two months before a planned pregnancy. Breastfeeding and contraception advice depends on the exact medicine, so discuss these before starting treatment.
For orforglipron, the US prescribing information advises people using oral contraceptives to add a barrier method or switch to a non-oral method for 30 days after starting and after each dose increase. This is a product-specific precaution.
Bring a complete medication list, including supplements. Insulin or sulfonylureas may need adjustment to reduce low-blood-sugar risk. Oral semaglutide can affect the handling of medicines such as levothyroxine, while orforglipron has additional interactions that need checking. Tell the team arranging anaesthesia or deep sedation that you use a GLP-1 medicine, because delayed stomach emptying can affect their preparation plan.
At Edwin Lim Medical Aesthetic Clinic, treatment begins with an in-person consultation. We assess your suitability and explain the reasons for any recommendation, including whether the proposed use falls within the medicine’s registered indication. Blood tests are arranged when clinically indicated rather than routinely for everyone.
If we prescribe a tablet, we explain how to take it, what you may notice and when to contact us. At follow-up, we look at your weight trend, appetite, eating and drinking, and any side effects. We also review blood sugar or blood pressure when relevant. The timing depends on your progress, with closer review sometimes needed when treatment begins or the dose changes.
You can WhatsApp the clinic with treatment questions. Persistent side effects or an unexpected response should be raised before your next planned review, while urgent symptoms require prompt medical care.
Learn more about our personalised medical weight-loss programme at https://edwinlimclinic.sg/personalised-medical-weight-loss-program-in-singapore/
When an appetite-regulating medicine is stopped, its effects can wear off and hunger may return. Some people regain weight, even after working hard to establish healthier habits. This reflects the continuing biological challenge of weight management and is a reason to plan ahead with your doctor.
The amount of regain varies. Findings from injectable treatment withdrawal studies should not be used to predict an exact percentage of regain after stopping a particular tablet. If treatment also controls diabetes, a plan for blood sugar management is essential.
Before stopping, we discuss why you want to stop, your current health and what support may help you maintain progress. A return of persistent hunger or a rising weight trend is a reason to review the plan early. There is no universal tapering schedule proven to prevent weight regain for every oral GLP-1 treatment.
Losing weight can include loss of muscle as well as fat. Try to keep regular, nourishing meals even when your appetite is lower, with suitable protein sources such as fish, eggs, tofu, beans or lean meat. Resistance exercise helps preserve strength; the type and intensity should suit your health and starting fitness.
Continue these habits after treatment changes. Adequate nutrition, manageable activity, sleep and periodic review support longer-term weight control, although they cannot guarantee that no weight will return. If eating becomes difficult or you feel progressively weaker, let us know so the plan can be reassessed.
At our clinic, oral semaglutide starts from $308 before GST for a month’s supply. Medication costs depend on the prescribed dose and supply and are confirmed before treatment. This starting price refers to the diabetes formulation; prices for the newer overseas-approved tablets are not quoted here.
The initial in-person consultation is $60 before GST. Follow-up consultations are also $60 before GST per consultation and are charged separately from medication.
When comparing costs, consider the ongoing medication price, likely treatment duration and follow-up consultations. We can explain these separately so that you understand what your treatment plan involves.
For appointments or questions about current clinic pricing, contact us at https://edwinlimclinic.sg/contact-number/ or WhatsApp https://wa.me/6596372218
You can start with the difficulties you are experiencing: persistent hunger, a routine that makes dosing difficult, previous side effects or concerns about injections. These details are often more helpful than arriving with a fixed choice of medicine. We can then consider the options in the context of your health and preferences.
For an overview of oral and injectable treatments, read our prescription medication guide at https://edwinlimclinic.sg/comprehensive-guide-to-weight-loss-medications-in-singapore/
Dr Edwin Lim
MBBS (Singapore), MRCS (Edinburgh), PgDip Practical Dermatology (Cardiff), MSc Practical Dermatology (Cardiff), Diploma in Aesthetic Medicine, (AAAM), Accredited by the Aesthetic Dermatology Educational Group (ADEG)
